Can chemo stop immunotherapy from backfiring in lung cancer?
NCT ID NCT07274384
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at people with advanced non-small cell lung cancer whose tumors have high PD-L1 levels. Some patients experience rapid tumor growth when treated with immunotherapy alone. The trial will test whether adding chemotherapy to the immunotherapy drug cemiplimab can prevent this dangerous reaction. About 74 participants will be randomly assigned to receive either immunotherapy alone or immunotherapy plus chemotherapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERPROGRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can a pill plus immunotherapy and targeted radiation shrink lung tumors before surgery?
- Can a targeted drug combo boost chemoradiation in EGFR-Positive lung cancer?
- Cancer drug pralsetinib may change how the body processes other medications
- Blood test may let cancer patients take safe breaks from immunotherapy
- New pill takes on tough lung cancer mutation